Synthesis and Structure of Arene Ru(II) N∧O‑Chelating Complexes: In Vitro Cytotoxicity and Cancer Cell Death Mechanism
journal contributionposted on 08.04.2020 by Sundarraman Balaji, Mohamed Kasim Mohamed Subarkhan, Rengan Ramesh, Hangxiang Wang, David Semeril
Any type of content formally published in an academic journal, usually following a peer-review process.
A panel of six new structurally related organometallic arene Ru(II) complexes of general composition [(η6-benzene)Ru(L)Cl] (1–3) and [(η6-p-cymene)Ru(L)Cl] (4–6) (L = dimethylaminobenzhydrazones) have been designed and synthesized in search of new ruthenium anticancer drugs. The identities of the synthesized complexes have been well-established by elemental analysis and various spectral (FT-IR, UV–vis, NMR, and HR-MS) methods. The solid-state molecular structures of the ruthenium complexes were determined with the help of X-ray crystallography and confirms the presence of a pseudo-octahedral geometry around ruthenium. Furthermore, cytotoxicity of the complexes has been unveiled with the aid of MTT assay against A549 (lung carcinoma), LoVo (colon adenocarcinoma), HuH-7 (hepato cellular carcinoma) along with the noncancerous 16HBE (human lung bronchial epithelium) cells and compared with the effect of the standard drug cisplatin. Interestingly, complexes 4, 5, and 6 which contain a p-cymene moiety induce a remarkable decrease of cell viability against all the cancer cells tested. The capacity corresponding to the inhibition of A549 cells proliferation was analyzed by 5-ethynyl-2-deoxyuridine (EdU) incorporation assay and indicated a notable effect of p-cymene counterparts 4, 5, and 6 over cisplatin. Further studies such as AO-EB (acridine orange–ethidium bromide) staining, flow cytometry, and Western blot analyses on cell death mechanism signified that the cytotoxicity was associated with apoptosis in cancer cells. This clearly suggests that p-cymene-capped Ru(II) complexes are also one of the propitious cancer therapeutic candidates and are worthy of further investigations.